Nuklearmedizin 2020; 59(02): 166
DOI: 10.1055/s-0040-1708352
Wissenschaftliche Poster
Leuchtfeuer
© Georg Thieme Verlag KG Stuttgart · New York

Perfusion-Phase 18 F-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neuronal Injury

L Beyer
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
A Nitschmann
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
H Barthel
2   University of Leipzig, Klinik und Poliklinik für Nuklearmedizin, Leipzig
,
T van Eimeren
3   University of Cologne, Klinik und Poliklinik für Nuklearmedizin, Köln
,
M Unterrainer
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
J Sauerbeck
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
M Song
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
ML Schroeter
4   University of Leipzig, Clinic for Cognitive Neurology, Leipzig
,
DS Russell
5   Molecular Neuroimaging, New Haven
,
A Stephens
6   Piramal Imaging GmbH, Berlin
,
J Herms
7   LMU München, Center for Neuropathology and Prion Research, München
,
J Levin
8   LMU München, Neurologische Klinik und Poliklinik, München
,
J Classen
9   University of Leipzig, Leipzig
,
G Höglinger
10   DZNE, München
,
P Bartenstein
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
V Villemagne
11   University of Melbourne, The Florey Institute of Neuroscience and Mental Health, Melbourne
,
A Drzezga
12   University of Cologne, Klinik und Poliklinik für Nuklearmedizin, Köln
,
J Seibyl
5   Molecular Neuroimaging, New Haven
,
O Sabri
9   University of Leipzig, Leipzig
,
M Brendel
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
› Author Affiliations
Further Information

Publication History

Publication Date:
08 April 2020 (online)

 

Ziel/Aim Second generation tau radioligands for use with positron emission tomography (PET) have been developed for visualization of tau deposits in vivo.For several β-amyloid and first generation tau radioligands, it has been shown that reduced early-phase perfusion can be used as a surrogate of neuronal injury. Therefore, we investigated the performance of early acquisitions of the novel tau radioligand18F-PI-2620 for the assessment of neuronal injury.

Methodik/Methods Twenty-six subjects were referred with suspected tauopathies and received a dynamic 18F-PI-2620 tau-PET (0-60 min p.i.) and 18F-fluorodeoxyglucose (FDG)-PET (30-50 min p.i.). Regional standard-uptake-value-ratios of early-phase perfusion images (single frame SUVr) and the blood flow estimate (R1) of 18F-PI-2620 were correlated with corresponding quantification of FDG-PET (global mean/cerebellar normalisation). Reduced tracer uptake in cortical target regions was also interpreted visually using 3-dimensional stereotactic surface projections by three experienced and three expert readers and intraclass correlation coefficients (ICC) were calculated between tau-PET perfusion and FDG-PET.

Ergebnisse/Results Highest agreement with FDG quantification was reached for 18F-PI-2620 acquisition from 0.5 to 2.5 min p.i. for global mean (R > 0.69) and cerebellar scaling (R > 0.63). Correlation coefficients (summed 0.5-2.5 min SUVr & R1) displayed excellent agreement in all cortical target regions for global mean (RSUVr0.75 ± 0.10, RR1= 0.75 ± 0.10) and cerebellar normalization (RSUVr0.67 ± 0.10, RR1= 0.67 ± 0.12). Visual interpretation revealed high regional ICC between tau-PET perfusion and FDG-PET independent of the reader experience (ICCSUVr= 0.62 ± 0.07, ICCR1= 0.66 ± 0.07).

Schlussfolgerungen/Conclusions Perfusion phase imaging of 18F-PI-2620 can serve as a surrogate biomarker for neuronal injury. Dynamic imaging or a dual time point protocol for tau-PET imaging could replace additional FDG-PET imaging by indexing both the distribution of tau and the amount of neuronal injury.